<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23357" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>IgA Nephropathy (Berger Disease)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Limaiem</surname>
            <given-names>Faten</given-names>
          </name>
          <aff>University of Tunis El Manar, Tunis Faculty of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faten Limaiem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23357.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Immunoglobulin A (IgA) nephropathy, or IgAN, also known as Berger disease, is&#x000a0;one of the&#x000a0;leading causes of glomerulonephritis and renal failure. This disease is a&#x000a0;prevalent form of glomerulonephritis characterized by the deposition of IgA in the glomerular basement membrane. Immune-mediated damage to the basement membrane results in hematuria, proteinuria, and renal insufficiency. Pathologically, a spectrum of glomerular lesions may be seen, with mesangial proliferation and prominent IgA deposition being the most commonly observed change.</p>
        <p>Despite being a common disease, accurate prevalence data for IgAN are limited due to the necessity of a renal biopsy to establish the diagnosis. Management entails inducing remission and preventing complications by addressing proteinuria, estimated glomerular filtration rate (GFR), blood pressure, and histological findings, while treatment strategies aim to mitigate immune reactions, reduce IgA deposition, and slow renal damage progression.&#x000a0;This activity comprehensively reviews the etiology, pathogenesis, evaluation, and management of IgAN while also explaining the role of the interprofessional healthcare team in evaluating and treating patients with this condition&#x000a0;effectively.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the clinical features and laboratory findings suggestive of IgA nephropathy.</p></list-item><list-item><p>Implement evidence-based management strategies for IgA nephropathy, including pharmacological interventions, lifestyle modifications, and dietary recommendations.</p></list-item><list-item><p>Assess the severity and progression of IgA nephropathy through regular monitoring of renal function, proteinuria, and other relevant parameters.</p></list-item><list-item><p>Collaborate with interprofessional healthcare providers to optimize IgA nephropathy management by selecting appropriate immunosuppressive agents and supportive therapies tailored to an individual's disease course and risk factors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23357&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23357">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23357.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Immunoglobulin A (IgA) nephropathy, or IgAN, is&#x000a0;one of the&#x000a0;leading causes of glomerulonephritis and renal failure.<xref ref-type="bibr" rid="article-23357.r1">[1]</xref><xref ref-type="bibr" rid="article-23357.r2">[2]</xref>&#x000a0;This disease is characterized by the deposition of IgA in the glomerular mesangium.&#x000a0;Immune-mediated damage to the basement membrane results in hematuria, proteinuria, and renal insufficiency.<xref ref-type="bibr" rid="article-23357.r3">[3]</xref> Berger and Hinglais were the first to describe the disease in 1968, hence it is also known as Berger disease.<xref ref-type="bibr" rid="article-23357.r4">[4]</xref>&#x000a0;Pathologically, a spectrum of glomerular lesions may be seen, yet the most frequently encountered change is mesangial proliferation with prominent IgA deposition.</p>
        <p>Recent international collaborative efforts have significantly advanced our understanding of the immunopathogenesis of IgAN, leading to important discoveries. Furthermore, the establishment of multicenter networks has facilitated the holistic design and execution of clinical trials, offering crucial insights into immunotherapy for IgAN.</p>
        <p>The clinical course typically progresses gradually, yet between 20%&#x000a0;and 50% of affected patients develop end-stage renal disease (ESRD) within 20 years of diagnosis. Prevalence varies based on ethnicity, race, geography, and genetics, with Asian patients being more commonly and severely affected.<xref ref-type="bibr" rid="article-23357.r5">[5]</xref><xref ref-type="bibr" rid="article-23357.r6">[6]</xref><xref ref-type="bibr" rid="article-23357.r7">[7]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23357.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>IgAN results from abnormal immune reactions, resulting in IgA deposits within the glomerulus, increased podocyte permeability, and interstitial fibrosis.<xref ref-type="bibr" rid="article-23357.r8">[8]</xref>&#x000a0;Although&#x000a0;IgAN is often preceded by an infectious disease, which triggers a dysregulated immune response, it is noteworthy that IgAN itself is not of an infectious etiology.&#x000a0;No evidence suggests that specific infectious agents cause IgAN. Instead, the immune system appears to be activated by various clinical and subclinical triggers, along with genetic factors related to IgA glycosylation.</p>
        <p>The potential etiologies underlying IgAN include the factors mentioned below.</p>
        <p>
<bold>Familial</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fewer than 10% of cases are due to familial IgAN.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>At least 18 different gene segments associated with IgAN have been identified.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Some of these genes include the&#x000a0;<italic toggle="yes">C1GALT1</italic> (a galactosyl transferase enzyme) and&#x000a0;<italic toggle="yes">C1GALT1C1</italic> (a molecular chaperone).<xref ref-type="bibr" rid="article-23357.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Sporadic or Idiopathic IgA Nephropathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>More than 90% of cases are sporadic.<xref ref-type="bibr" rid="article-23357.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>No evidence suggests the involvement of&#x000a0;a particular infectious agent despite the association between macroscopic hematuria and mucosal inflammation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>No evidence indicates hypersensitivity to food antigens, except for a small group of patients with celiac disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Abnormal O-glycosylation of the IgA1 hinge region promotes the formation of circulating IgA1-antibody immune complexes, leading to mesangial cell activation and deposition.<xref ref-type="bibr" rid="article-23357.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Systemic Diseases Causing Secondary IgA Nephropathy</bold>
</p>
        <p>Many systemic conditions are associated with IgA deposits, causing IgAN pathology. Recent reports suggest the pathways leading to glomerular injury are similar between primary and secondary IgAN.<xref ref-type="bibr" rid="article-23357.r5">[5]</xref>&#x000a0;Secondary IgAN may arise from various conditions, including liver, gastrointestinal, autoimmune, dermatological, infectious, and drug-related causes.<xref ref-type="bibr" rid="article-23357.r5">[5]</xref><xref ref-type="bibr" rid="article-23357.r8">[8]</xref><xref ref-type="bibr" rid="article-23357.r11">[11]</xref>&#x000a0;Notably, it&#x000a0;is essential to differentiate primary from secondary IgAN, as secondary forms typically do not require treatment with immunosuppressive agents; instead, the focus is on addressing the underlying cause.<xref ref-type="bibr" rid="article-23357.r12">[12]</xref></p>
        <p>The significance of mucosal-associated lymphoid tissue (MALT) has recently gained prominence in understanding the pathology of various diseases, especially IgAN, as IgA production predominantly occurs in mucosal tissue. The primary role of MALT is to provide defense against environmental toxins and microbes. MALT tissue is predominantly located in the gut, particularly in Peyer's patches and lymphoid follicles, as well as in the tonsils, both of which are implicated in the pathogenesis of IgAN.<xref ref-type="bibr" rid="article-23357.r13">[13]</xref></p>
        <p><bold>Gastrointestinal&#x000a0;disorders:</bold>&#x000a0;Gastrointestinal disorders span a diverse range of conditions, each with distinct implications for IgAN.</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver disease: Liver disease is often associated with IgAN through various mechanisms, making it the most common cause of secondary IgAN.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_37048809">[5]</ext-link><xref ref-type="bibr" rid="article-23357.r12">[12]</xref>
<list list-type="bullet"><list-item><p>Usually, the liver plays a crucial role in clearing large IgA complexes, but this clearance process is compromised in liver disease, which explains the IgAN association.<xref ref-type="bibr" rid="article-23357.r14">[14]</xref></p></list-item><list-item><p>Bacterial translocation from leaky intestines, which is often increased in hepatic disease, can further exacerbate IgAN.</p></list-item><list-item><p>Cirrohisis is commonly associated with IgAN, and case reports have shown improvement in renal parameters with steroid treatment.<xref ref-type="bibr" rid="article-23357.r15">[15]</xref><xref ref-type="bibr" rid="article-23357.r16">[16]</xref></p></list-item><list-item><p>Other rare liver disorders disorders such as hemochromatosis, Wilson disease, and autoimmune hepatitis have also been potentially linked to IgAN.<xref ref-type="bibr" rid="article-23357.r12">[12]</xref><xref ref-type="bibr" rid="article-23357.r17">[17]</xref><xref ref-type="bibr" rid="article-23357.r18">[18]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Celiac disease: Celiac disease is strongly correlated with IgAN and shares an autoimmune origin.
<list list-type="bullet"><list-item><p>Celiac disease is linked with&#x000a0;HLA-DQ2/HLA-DQ8 haplotype.<xref ref-type="bibr" rid="article-23357.r19">[19]</xref></p></list-item><list-item><p>The enzyme transglutaminase 2 can activate B cells, leading to the production of IgG and IgA autoantibodies.</p></list-item><list-item><p>Transglutaminase 2 interacts with transferrin receptor-1, resulting in IgA1 deposition in the renal mesangium.</p></list-item><list-item><p>For patients diagnosed with IgAN presenting gastrointestinal symptoms, it is reasonable to implement a trial of a gluten-free diet and initiate further diagnostic workup.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory bowel disease: Inflammatory bowel disease poses a risk factor for IgAN.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_37048809">[5]</ext-link>
<list list-type="bullet"><list-item><p>Inflammatory bowel disease has 2 forms&#x02014;Crohn disease and ulcerative colitis, and IgAN is strongly associated with mortality in both conditions.</p></list-item><list-item><p>A common pathogenesis for both diseases&#x000a0;may involve&#x000a0;B-cell immunoglobulin oversecretion and CD4+ T cell (helper T cell) dysregulation.<xref ref-type="bibr" rid="article-23357.r5">[5]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Abnormal intestinal microbiota: Abnormal intestinal microbiota, comprising commensal gut bacteria, are highly associated with IgAN.<xref ref-type="bibr" rid="article-23357.r13">[13]</xref><xref ref-type="bibr" rid="article-23357.r20">[20]</xref>&#x000a0;Studies indicate that patients with IgAN exhibit a reduced diversity of the gut microbiome, notably in the <italic toggle="yes">Clostridium</italic>, <italic toggle="yes">Enterococcus</italic>, and <italic toggle="yes">Lactobacillus genera</italic>, compared to healthy controls.<xref ref-type="bibr" rid="article-23357.r13">[13]</xref>&#x000a0;Some&#x000a0;researchers have proposed probiotics as a potential therapeutic measure.</p>
          </list-item>
        </list>
        <p><bold>Autoimmune disorders:&#x000a0;</bold>Autoimmune disorders, including Sj&#x000f6;gren syndrome, spondyloarthritis, systemic lupus erythematosus, and Beh&#x000e7;et disease, have been associated with the development of IgA.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_37048809">[5]</ext-link><xref ref-type="bibr" rid="article-23357.r9">[9]</xref>&#x000a0;</p>
        <p><bold>Dermatological&#x000a0;disorders:&#x000a0;</bold>Dermatological disorders encompass a range of conditions, some of which are associated with IgAN.</p>
        <list list-type="bullet">
          <list-item>
            <p>Psoriasis: Psoriasis is recognized as the predominant skin condition associated with IgAN. Additional dermatological conditions&#x000a0;associated with IgAN include dystrophic epidermolysis bullosa, juvenile dermatomyositis, and leukocytic vasculitis.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_37048809">[5]</ext-link></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Leukocytoclastic vasculitis: Leukocytoclastic vasculitis, a rare type III allergic reaction, leads to immune-complex mediated vasculitis in the dermal small blood vessels, resulting in erythematous macules and palpable purpura, which may progress to ulcers, blood blisters, or necrosis. This condition can manifest renal involvement and be associated with IgA deposits in the kidney, leading to secondary IgAN.<xref ref-type="bibr" rid="article-23357.r21">[21]</xref>&#x000a0;Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/24215">Leukocytoclastic Vasculitis</ext-link>," for further information.</p>
          </list-item>
        </list>
        <p><bold>Infectious diseases:&#x000a0;</bold>Clinical symptoms of IgAN, including gross hematuria, are highly associated with preceding viral or bacterial infections, most often an upper respiratory tract infection (URI). Please refer to the Pathophysiology section for further details. Infectious agents induce mucosal injury, resulting in dysregulated IgA production and deposition.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The&#x000a0;co-occurrence of a URI and macroscopic hematuria is so prevalent that it has earned its own designation&#x02014;synpharyngitic hematuria.&#x000a0;Additionally, tonsillar inflammation (attributed to commensal organisms, such as&#x000a0;<italic toggle="yes">Hemophilus parainfluenza,&#x000a0;Prevotella,&#x000a0;<italic toggle="yes">Fusobacterium</italic>,&#x000a0;<italic toggle="yes">Sphingomonas</italic>, </italic>and&#x000a0;<italic toggle="yes"><italic toggle="yes">Treponema</italic></italic> spp) is&#x000a0;considered&#x000a0;a contributing factor.<xref ref-type="bibr" rid="article-23357.r8">[8]</xref><xref ref-type="bibr" rid="article-23357.r22">[22]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Viral infections caused by COVID-19, HIV, and hepatitis B are also strongly associated with IgAN.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_37048809">[5]</ext-link></p>
          </list-item>
        </list>
        <p><bold>Drug-related IgAN:&#x000a0;</bold>Drug-induced IgAN involves diagnosing renal injury timing in relation to medication administration and ruling out other potential causes. Tumor necrosis factor-&#x003b1; (TNF-&#x003b1;) inhibitors are notably associated with IgAN due to their immunomodulatory effects. Possible mechanisms include the reaction of IgG antiglycan antibodies against the glycan on TNF-&#x003b1; inhibitor heavy chains or the binding of hypoglycosylated IgA1 to antigens on TNF-&#x003b1; inhibitors. Examples of TNF-&#x003b1; inhibitors include adalimumab and infliximab.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_37048809">[5]</ext-link>&#x000a0;</p>
        <p>Other medications associated with secondary IgAN include interleukins 12 and 23 inhibitors, immune checkpoint inhibitors, direct oral anticoagulants, warfarin, and thioureylene derivatives used for Graves disease.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_37048809">[5]</ext-link></p>
        <p>
<bold>Additional Causes</bold>
</p>
        <p>Although uncommon, primary pulmonary diseases, such as sarcoidosis, idiopathic pulmonary fibrosis, or pulmonary hemorrhage, can be associated with IgAN.<xref ref-type="bibr" rid="article-23357.r23">[23]</xref><xref ref-type="bibr" rid="article-23357.r24">[24]</xref>&#x000a0;In addition, oncological processes, such as myeloproliferative disease, gastric carcinoma, lung cancers, renal cell carcinomas, and other malignancies, can also be associated with IgA.<xref ref-type="bibr" rid="article-23357.r25">[25]</xref><xref ref-type="bibr" rid="article-23357.r26">[26]</xref><xref ref-type="bibr" rid="article-23357.r27">[27]</xref></p>
      </sec>
      <sec id="article-23357.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Although IgAN is the most common cause of glomerulonephritis, its exact prevalence remains uncertain due to many cases being asymptomatic and requiring a renal biopsy for definitive diagnosis. Not all patients undergo a biopsy to confirm the diagnosis, with some opting for conservative management, particularly if they exhibit a benign variant. Approximately 10% of renal biopsies in the United States reveal IgAN, while the prevalence is higher in East Asia (up to 40% of biopsies) and Europe (20% to 30% of biopsies).<xref ref-type="bibr" rid="article-23357.r4">[4]</xref><xref ref-type="bibr" rid="article-23357.r14">[14]</xref><xref ref-type="bibr" rid="article-23357.r28">[28]</xref>&#x000a0;A systematic analysis of biopsy-based literature across multiple countries indicates an overall incidence of over 2.5 per 100,000.<xref ref-type="bibr" rid="article-23357.r14">[14]</xref><xref ref-type="bibr" rid="article-23357.r29">[29]</xref></p>
        <p>Routine screening of hematuria in East Asian schoolchildren is believed to contribute&#x000a0;to&#x000a0;the early detection of microscopic hematuria, thereby contributing to the increased diagnosis of IgAN. However, data from dialysis and biopsy registries indicate a greater burden of IgAN in East and Pacific Asian countries. These findings align with geospatial differences in the prevalence of genetic susceptibility loci&#x000a0;observed in global genome-wide association studies.<xref ref-type="bibr" rid="article-23357.r30">[30]</xref><xref ref-type="bibr" rid="article-23357.r31">[31]</xref><xref ref-type="bibr" rid="article-23357.r32">[32]</xref>&#x000a0;In addition, evidence also suggests that ESRD is more common among East Asian patients diagnosed with IgAN than non-Asian patients.<xref ref-type="bibr" rid="article-23357.r33">[33]</xref></p>
        <p>In the United States, IgAN appears to affect White populations more than Black individuals disproportionately.<xref ref-type="bibr" rid="article-23357.r28">[28]</xref> The disease commonly manifests in children and young adults, with a peak incidence in the second and third decades of life. A male predominance ratio of about 2.5:1 is present in the United States and Europe, whereas the ratio is closer to 1:1 in East Asia.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref><xref ref-type="bibr" rid="article-23357.r34">[34]</xref></p>
      </sec>
      <sec id="article-23357.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>A multi-hit model has been proposed that suggests abnormal immune regulation at the core of IgAN pathogenesis, with susceptibility influenced by various genetic and environmental factors.<xref ref-type="bibr" rid="article-23357.r35">[35]</xref> These "hits" are evident in the IgA moieties detected in biopsies and circulating in IgAN patients. Notably, immune complexes composed of galactose-deficient IgA1 are central in the circulation and glomeruli of individuals with IgAN.</p>
        <p>
<bold>Genetic Factors</bold>
</p>
        <p>The presence of abnormally glycosylated IgA1 is a heritable trait.<xref ref-type="bibr" rid="article-23357.r36">[36]</xref>&#x000a0;In a quarter of blood relatives of IgAN patients, galactose-deficient IgA1 levels are elevated, and segregation analysis reveals a likely major dominant gene inheritance with a polygenic background.<xref ref-type="bibr" rid="article-23357.r37">[37]</xref></p>
        <p>
<bold>Environmental Factors</bold>
</p>
        <p>Glomerular inflammation and mesangial proliferation are thought to occur due to nephritogenic immune complexes. Activation of the renin-angiotensin and complement systems further leads to glomerulosclerosis and tubulointerstitial fibrosis, contributing to impaired renal function. Additionally, risk factors such as smoking and hypertension exacerbate disease progression by inducing microvascular injury.<xref ref-type="bibr" rid="article-23357.r38">[38]</xref>&#x000a0;Glmoerulomegaly and maladaptive hyperfiltration injury attributed to obesity may also be implicated in the nonimmunological progression of the disease.<xref ref-type="bibr" rid="article-23357.r39">[39]</xref></p>
        <p>A proposed 4-hit model highlights abnormal mucosal IgA regulation as the central mechanism:<xref ref-type="bibr" rid="article-23357.r5">[5]</xref><xref ref-type="bibr" rid="article-23357.r10">[10]</xref><xref ref-type="bibr" rid="article-23357.r35">[35]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Abnormal O-glycosylation of the IgA1 hinge region, leading to increased levels of galactose-deficient IgA1.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Production of anti-glycan antibodies and IgA1 autoantibodies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Formation of IgA1 immune complexes circulating in the bloodstream and depositing in the kidney.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Activation of mesangial cells, as well as the lectin and alternative complement systems, resulting in the release of cytokines, the deposition of extracellular proteins, and systemic inflammation and fibrosis.</p>
          </list-item>
        </list>
        <p>The first "hit" involves a genetically susceptible host predisposed to developing a dysregulated immune response, primarily involving mucosal immunity. IgA comprises 15% of all immunoglobulins and is primarily present in the mucosa and bloodstream. IgA exists in 2 forms&#x02014;IgA1 and IgA2&#x02014;and each of these can be monomeric or polymeric.<xref ref-type="bibr" rid="article-23357.r6">[6]</xref>&#x000a0;In genetically susceptible patients, a&#x000a0;precipitating factor, such as infection, can trigger B cells to produce the abnormal IgA, which is missing a galactose molecule at the hinge region.<xref ref-type="bibr" rid="article-23357.r7">[7]</xref><xref ref-type="bibr" rid="article-23357.r40">[40]</xref>&#x000a0;Trivial mucosal infections, chronic exposure to pathogens, and abnormal handling of commensals in the gut have all been hypothesized to trigger the abnormal immune response. The resulting hypoglycosylation enables the aberrant IgA molecules to self-aggregate.<xref ref-type="bibr" rid="article-23357.r6">[6]</xref><xref ref-type="bibr" rid="article-23357.r7">[7]</xref></p>
        <p>Elevated galactose-deficient IgA alone is insufficient to cause IgAN; relatives of IgAN patients have demonstrated elevated levels of abnormally glycosylated IgA1 without developing the disease.<xref ref-type="bibr" rid="article-23357.r14">[14]</xref> The second "hit" occurs when abnormal IgA1 triggers autoantibodies against IgA1 and anti-glycan IgGs.<xref ref-type="bibr" rid="article-23357.r7">[7]</xref><xref ref-type="bibr" rid="article-23357.r41">[41]</xref> Normally, IgA complexes are cleared by the liver, which is why liver disease is highly associated with IgAN.<xref ref-type="bibr" rid="article-23357.r8">[8]</xref></p>
        <p>The third "hit" is the formation of abnormal IgA1 complexes, which circulate in the bloodstream and deposit in the mesangium. This leads to the final "hit" of mesangial cytokine release and complement activation. Cytokine release activates podocytes, causing glomerular permeability and tubular interstitial damage, which leads to interstitial fibrosis, tubular damage, and inflammatory cell infiltration.<xref ref-type="bibr" rid="article-23357.r6">[6]</xref>&#x000a0;The inflammatory cell infiltrate especially involves macrophages and dendritic cells.</p>
        <p>Activation of complement plays a significant role in the pathogenesis of IgAN, with particular emphasis on the mannose-binding lectin pathway. Polymeric IgA1 can activate this pathway, and components of this lectin pathway, including complement factor H and properdin, are detected within glomerular deposits.<xref ref-type="bibr" rid="article-23357.r42">[42]</xref><xref ref-type="bibr" rid="article-23357.r43">[43]</xref><xref ref-type="bibr" rid="article-23357.r44">[44]</xref>&#x000a0;In addition, the alternative complement system is activated,&#x000a0;and immune complexes containing C3 (usually in the same distribution as IgA1) are observed in approximately 90% of IgAN kidney biopsy samples on immunofluorescence staining.<xref ref-type="bibr" rid="article-23357.r7">[7]</xref>&#x000a0;</p>
        <p>These 2 complement activation pathways, the lectin and alternative pathways, are pivotal in causing glomerular basement membrane damage. The damaged basement membrane results in the ultrafiltration of larger molecules and produces hematuria.<xref ref-type="bibr" rid="article-23357.r7">[7]</xref>&#x000a0;However, the pathophysiology underlying why some individuals develop asymptomatic hematuria while others progress to rapidly progressive glomerulonephritis, ultimately leading to renal failure, remains poorly understood.<xref ref-type="bibr" rid="article-23357.r45">[45]</xref></p>
      </sec>
      <sec id="article-23357.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Microscopically, secondary and primary IgAN are indistinguishable unless manifestations of secondary disease are seen.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref> Histologically, IgAN is characterized by the following characteristics (see <bold>Image.</bold>&#x000a0;Histopathological Characteristics of IgA Nephropathy):&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse proliferation of mesangial cells and matrix.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypercellular or&#x000a0;normal glomeruli with diffuse necrotizing crescentic glomerulonephritis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Mesangial involvement resembling focal and segmental glomerulosclerosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immunofluorescence reveals a diffuse granular pattern of IgA deposits in the mesangium.</p>
          </list-item>
        </list>
        <p>
<bold>Light Microscopy</bold>
</p>
        <p>Common findings on light microscopy include focal or diffuse mesangial proliferation and expansion of the extracellular matrix.<xref ref-type="bibr" rid="article-23357.r46">[46]</xref> Morphology reveals intracapillary and extracapillary proliferative lesions. Focal glomerular sclerosis, sometimes indistinguishable from focal segmental glomerulosclerosis, may occur. Interstitial fibrosis, vascular sclerosis, and tubular atrophy are evident in advanced stages. Segmental necrotizing areas with crescent formation may appear in some patients due to extensive capillary disruption.</p>
        <p>
<bold>Electron Microscopy</bold>
</p>
        <p>Electron microscopy reveals mesangial hypercellularity and excess mesangial matrix. An important finding is the presence of mesangial electron-dense deposits of IgA. However, subepithelial and subendothelial&#x000a0;deposits of the glomerular capillary wall are seen in a minority of patients, particularly those with the more severe form of the disease.<xref ref-type="bibr" rid="article-23357.r47">[47]</xref></p>
        <p>
<bold>Immunofluorescence</bold>
</p>
        <p>Immunofluorescence examination reveals mesangial IgA deposits in a diffuse granular pattern, primarily consisting of polymeric IgA of the IgA1 subclass. Additionally, IgG is detected in 43% of patients and IgM in 54%.<xref ref-type="bibr" rid="article-23357.r35">[35]</xref> C3 is commonly present and typically co-deposits with IgA deposits; its deposition correlates with disease severity and is absent in asymptomatic deposits.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref>&#x000a0;Other&#x000a0;components of the lectin and alternative complement pathways are also frequently found. C1q staining is usually absent, indicating a lack of activation of the classical complement pathway.</p>
        <p>C4d, a marker of the lectin complement pathways, imparts a worse prognosis.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_25694468">[7]</ext-link><xref ref-type="bibr" rid="article-23357.r48">[48]</xref>&#x000a0;Another potentially quantifiable assessment is the maximal glomerular diameter, which is significantly correlated with loss of glomerular filtration rate (GFR) and proteinuria.<xref ref-type="bibr" rid="article-23357.r41">[41]</xref><xref ref-type="bibr" rid="article-23357.r49">[49]</xref></p>
        <p>
<bold>Proteinuria</bold>
</p>
        <p>Nephrotic-range proteinuria is more common in children than in adults. In pediatric patients, renal biopsy may show widespread podocyte foot process effacement along with IgA mesangial deposits representing co-occurrence of minimal change disease and IgAN. The mesangial deposits may remain, although foot process effacement and proteinuria often resolve with steroids.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref></p>
      </sec>
      <sec id="article-23357.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In most patients with IgAN, history and physical examination are typically unremarkable. The primary complaint often revolves around gross hematuria, which can manifest as brown, red, or "coca-cola colored" urine. Acute renal failure may lead to ankle edema, facial puffiness, and hypertension. Other potential symptoms include frothy urine or the presence of a rash. Patients may report a recent history of URIs, such as pharyngitis, preceding the onset of hematuria.<xref ref-type="bibr" rid="article-23357.r50">[50]</xref>&#x000a0;Additionally, a history of hematuria associated with intense exercise may be present.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref> Reviewing prior urinalysis reports can provide valuable insights when available.</p>
        <p>During a physical examination, it is essential to assess blood pressure and observe for indications of diminished renal function, including edema, ascites, and basal lung crepitations. Hypertension is a common manifestation in IgAN. In addition, IgAN may coexist with cirrhosis, liver diseases, and celiac disease. Therefore, conducting a comprehensive general and abdominal examination is crucial for excluding these clinically significant comorbidities.&#x000a0;The range of clinical&#x000a0;features of IgAN is broad, ranging from asymptomatic hematuria to rapidly progressive glomerulonephritis. The mode of presentation varies based on age group and histological biopsy patterns. Among the most prevalent clinical phenotypes are asymptomatic hematuria and progressive kidney disease.</p>
        <p>Asymptomatic hematuria with mild proteinuria, typically around 0.5 g/d, may be detected during routine screening. A subset of individuals presenting with isolated microscopic hematuria and mild proteinuria may eventually progress to develop substantial proteinuria and hypertension, underscoring the importance of long-term monitoring.<xref ref-type="bibr" rid="article-23357.r51">[51]</xref> Progressive&#x000a0;chronic kidney disease (CKD) is frequently observed in various cohorts. Renal survival rates exhibit significant variability depending on factors such as biopsy timing and the presence of lead-time bias. Estimated renal survival at the 10-year mark is thought to be between 57% and 91%.<xref ref-type="bibr" rid="article-23357.r52">[52]</xref></p>
        <p>Synpharyngitic macroscopic hematuria is often the initial presentation of IgAN,&#x000a0;with patients seeking medical attention due to the simultaneous occurrence of gross hematuria and pharyngitis or another infection. Recurrent episodes of macroscopic hematuria are also common. While nephrotic-range proteinuria can occur in IgAN, the simultaneous presence of the 2 conditions is rare.<xref ref-type="bibr" rid="article-23357.r53">[53]</xref><xref ref-type="bibr" rid="article-23357.r54">[54]</xref></p>
        <p>Extrarenal manifestations of IgAN are not uncommon or unsurprising, given the systemic nature of the disease. Studies have shown that up to 35% of patients experience gastrointestinal symptoms, including abdominal pain, cramping, and diarrhea.<xref ref-type="bibr" rid="article-23357.r8">[8]</xref></p>
        <p>Less than 5% of patients with IgAN present with acute kidney injury,&#x000a0;typically resulting from either the rapid&#x000a0;development of crescents or&#x000a0;tubular damage or obstruction due to gross hematuria and RBC casts. Although aggressive immunosuppressive treatment is often necessary in crescent formation, damage from large amounts of RBCs is usually reversible with supportive treatment.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref></p>
      </sec>
      <sec id="article-23357.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation begins with establishing the diagnosis. The initial investigation involves urine analysis to detect microscopic hematuria. The presence of red cells and red cell casts indicates glomerular injury and potential active disease. Proteinuria is assessed using the protein-to-creatinine ratio in urine or 24-hour urinary protein excretion. Serum creatinine and estimated GFR are measured to quantify renal function.</p>
        <p>Confirmation of the diagnosis relies&#x000a0;on renal biopsy, which allows for detailed examination of renal histology using light microscopy, electron microscopy, and immunofluorescence. Immunofluorescence, specifically demonstrating the deposit of IgA in the glomerular basement membrane,&#x000a0;is the gold standard for diagnosis. Additionally, IgAN should be classified using the Oxford classification to predict prognosis. This Oxford classification system integrates histological, clinical, and biomarker criteria to provide valuable prognostic insights.</p>
        <p>The Oxford classification relies on the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mesangial cellularity</p>
          </list-item>
          <list-item>
            <p>Endocapillary proliferation</p>
          </list-item>
          <list-item>
            <p>Segmental glomerulosclerosis</p>
          </list-item>
          <list-item>
            <p>Tubular atrophy or interstitial fibrosis&#x000a0;<xref ref-type="bibr" rid="article-23357.r55">[55]</xref><xref ref-type="bibr" rid="article-23357.r56">[56]</xref></p>
          </list-item>
        </list>
        <p>Various studies have validated these criteria, with tubular atrophy or interstitial fibrosis being the most predictive of poor prognosis.<xref ref-type="bibr" rid="article-23357.r14">[14]</xref><xref ref-type="bibr" rid="article-23357.r57">[57]</xref><xref ref-type="bibr" rid="article-23357.r58">[58]</xref><xref ref-type="bibr" rid="article-23357.r59">[59]</xref>&#x000a0;Fibroblast markers, such as FSP1 and URG11, are inversely correlated with GFR and prognosis. Notably, the inclusion of a criterion to assess the presence of crescents remains controversial. Current KDIGO criteria&#x000a0;do not support using this as a prognostic indicator; instead, the presence of crescents adds to the severity of the overall clinical presentation.<xref ref-type="bibr" rid="article-23357.r48">[48]</xref><xref ref-type="bibr" rid="article-23357.r60">[60]</xref></p>
        <p>Other possible markers of IgAN include urinary markers&#x000a0;assessing components of the complement pathway, such as urinary C4d, serum C3 levels, and other serum markers of alternative and lectin complement pathways.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopupWithQuestions/166172#link_25694468">[7]</ext-link> Serum IgA levels lack sensitivity and specificity for IgAN diagnosis. Although galactose-deficient IgA levels are elevated in patients with IgAN, notably, these levels can also be elevated in relatives of IgAN patients without clinical disease. A study suggests that&#x000a0;these markers exhibit a sensitivity of 77% and a specificity of 94%.<xref ref-type="bibr" rid="article-23357.r14">[14]</xref><xref ref-type="bibr" rid="article-23357.r61">[61]</xref><xref ref-type="bibr" rid="article-23357.r62">[62]</xref>&#x000a0;In addition, IgA and IgG autoantibodies against abnormally glycosylated IgA1 are elevated in patients with IgAN, although the measurement of these levels is not often available outside the research setting.<xref ref-type="bibr" rid="article-23357.r14">[14]</xref><xref ref-type="bibr" rid="article-23357.r61">[61]</xref></p>
      </sec>
      <sec id="article-23357.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of IgAN begins with confirming the diagnosis, typically through a renal biopsy, while ruling out secondary causes. Key considerations for formulating the management plan include assessing proteinuria, eGFR, blood pressure, and histological findings. The primary goals of treatment are to induce remission and avert the onset of complications.<xref ref-type="bibr" rid="article-23357.r63">[63]</xref></p>
        <p>First-line agents for managing&#x000a0;proteinuria and lowering blood pressure in IgAN patients typically involve angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). The target blood pressure is typically set at 130/80 mm Hg.<xref ref-type="bibr" rid="article-23357.r64">[64]</xref>&#x000a0;If proteinuria is more than 1 g/d, the&#x000a0;systolic blood pressure target is less than 125 mm Hg.</p>
        <p>
<bold>Conservative Therapy</bold>
</p>
        <p>Conservative therapy plays a crucial role in managing IgAN by reducing proteinuria and slowing the rate of renal function decline in IgAN, which cannot be overemphasized. In the Supportive Versus Immunosuppressive Therapy of Progressive IgA Nephropathy (STOP-IgAN) study,&#x000a0;around one-third of patients achieved satisfactory outcomes without requiring immunosuppressive therapy following a 6-month trial of optimizing conservative measures, including aggressive ACE inhibitors or ARB titration (optimal medical management).<xref ref-type="bibr" rid="article-23357.r65">[65]</xref>&#x000a0;In this study, the comparison between immunosuppressive therapy and optimal medical management alone revealed no significant improvement in primary outcomes&#x02014;death, ESRD, or a decline in GFR exceeding 40%&#x02014;among those receiving immunosuppressive treatment during the 3-year and 10-year follow-up periods.<xref ref-type="bibr" rid="article-23357.r66">[66]</xref><xref ref-type="bibr" rid="article-23357.r67">[67]</xref><xref ref-type="bibr" rid="article-23357.r68">[68]</xref></p>
        <p>The role of renin-angiotensin system blockade in IgAN is firmly established. However, caution is warranted against dual renin-angiotensin system blockade due to the risk of hyperkalemia.<xref ref-type="bibr" rid="article-23357.r69">[69]</xref>&#x000a0;In addition, considering the association between smoking and IgAN progression, advising patients to quit smoking is essential.<xref ref-type="bibr" rid="article-23357.r38">[38]</xref><xref ref-type="bibr" rid="article-23357.r66">[66]</xref><xref ref-type="bibr" rid="article-23357.r67">[67]</xref>&#x000a0;Salt intake, lipid management, weight loss, and smoking cessation are also advised. Smoking has been shown to independently increase the risk of IgAN progression, and this effect worsens with GFR decline.<xref ref-type="bibr" rid="article-23357.r70">[70]</xref></p>
        <p>
<bold>Corticosteroids</bold>
</p>
        <p>Corticosteroids are&#x000a0;crucial in reducing proteinuria in IgAN, particularly when levels exceed 1g/d. Steroid administration has especially been shown to decrease proteinuria. Typically, a tapering course of prednisone is prescribed for 2 to 4 months.<xref ref-type="bibr" rid="article-23357.r71">[71]</xref><xref ref-type="bibr" rid="article-23357.r72">[72]</xref><xref ref-type="bibr" rid="article-23357.r73">[73]</xref></p>
        <p>The TESTING trial, which focused on patients with IgAN and proteinuria exceeding 1 g/d, demonstrated that treatment with methylprednisolone for 6 to 9 months significantly slowed disease progression compared to placebo. However, due to an excess of infections and adverse events, the initial dose of methylprednisolone had to be reduced, and cotrimoxazole prophylaxis for opportunistic infections was added.<xref ref-type="bibr" rid="article-23357.r74">[74]</xref><xref ref-type="bibr" rid="article-23357.r75">[75]</xref>&#x000a0;Nonetheless, longer-term data suggests that these effects may not be long-lasting.<xref ref-type="bibr" rid="article-23357.r68">[68]</xref><xref ref-type="bibr" rid="article-23357.r65">[65]</xref>&#x000a0;</p>
        <p>
<bold>Novel Agents</bold>
</p>
        <p>In recent years, the approval of several novel medications holds promise for significantly improving outcomes in IgAN.&#x000a0;</p>
        <p><bold>Sparsentan:</bold> Sparsentan is a non-immunosuppressive, novel dual endothelin and angiotensin receptor antagonist, which received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of IgAN in February 2023.<xref ref-type="bibr" rid="article-23357.r76">[76]</xref>&#x000a0;The&#x000a0;PROTECT trial was a multicenter randomized controlled trial that compared the effects of irbesartan (300 mg) with sparsentan (400 mg) on proteinuria in patients with persistent proteinuria despite maximal ACE inhibitor or ARB therapy. Results showed that the sparsentan group exhibited significantly less proteinuria and a trend toward preserved GFR compared to the irbesartan group.<xref ref-type="bibr" rid="article-23357.r77">[77]</xref><xref ref-type="bibr" rid="article-23357.r78">[78]</xref></p>
        <p><bold>Budesonide:</bold> Budesonide, in the form of oral nefecon, is a novel therapy for IgAN. This formulation consists of budesonide packaged in a pH-sensitive capsule, which preferentially releases the active drug at the terminal ileum near Peyer patches&#x02014;the site of significant IgA-producing lymphoid tissue. This targeted delivery system enables extensive first-pass metabolism, minimizing systemic effects.<xref ref-type="bibr" rid="article-23357.r68">[68]</xref><xref ref-type="bibr" rid="article-23357.r79">[79]</xref>&#x000a0;Results from the NEFIGAN and NeflgArd trials have shown significant reductions in proteinuria and preservation of GFR with the use of nefecon. Ongoing data analysis from these trials continues to provide insights into its efficacy.<xref ref-type="bibr" rid="article-23357.r80">[80]</xref><xref ref-type="bibr" rid="article-23357.r81">[81]</xref></p>
        <p><bold>Sodium-glucose cotransporter-2 (SGLT2) inhibitors:</bold> SGLT inhibitors demonstrated significant efficacy in slowing the progression of CKD. The DAPA-CKD and EMPA-KIDNEY trials were terminated early due to the evident benefits of SGLT2 inhibitors. Although these trials primarily included patients with all-cause CKD, a significant number of patients from both trials were diagnosed with IgAN. Further studies are needed to evaluate the effects of SGLT2 inhibitors on patients with IgAN.<xref ref-type="bibr" rid="article-23357.r68">[68]</xref><xref ref-type="bibr" rid="article-23357.r82">[82]</xref></p>
        <p>
<bold>Other Immunosuppressive Agents</bold>
</p>
        <p><bold>Mycophenolate mofetil&#x000a0;(MMF):</bold>&#x000a0;MMF has been studied for its potential to prevent IgAN progression, with studies being equivocal and findings varying across studies, particularly those conducted in Europe and North America. The majority of studies&#x000a0;are limited by small sample size.<xref ref-type="bibr" rid="article-23357.r83">[83]</xref>&#x000a0;However, some trials conducted in Asia have shown improvement and promising outcomes in terms of reducing proteinuria and preserving GFR with MMF.<xref ref-type="bibr" rid="article-23357.r84">[84]</xref><xref ref-type="bibr" rid="article-23357.r85">[85]</xref>&#x000a0;Notably, the MAIN trial, a recent randomized controlled trial in China, showcased significant reductions in proteinuria and preservation of GFR with MMF. This underscores the potential differences in disease progression among East Asian variants of IgAN compared to other regions globally.<xref ref-type="bibr" rid="article-23357.r84">[84]</xref><xref ref-type="bibr" rid="article-23357.r68">[68]</xref></p>
        <p><bold>Rituximab:</bold> This drug demonstrated efficacy in various glomerular diseases but has shown less promising results in early studies involving IgAN. A pilot study comparing rituximab to conservative management in patients with proteinuria showed no beneficial effects on proteinuria or renal function.<xref ref-type="bibr" rid="article-23357.r86">[86]</xref></p>
        <p><bold>Iptacopan:</bold> Iptacopan binds Factor B in the alternative complement pathway and prevents the formation of C3 convertase (C3bBb). APPLAUSE-IgAN is a phase III study evaluating ipatacopan compared to placebo in patients with biopsy-proven IgAN with a high risk of progression, and preliminary results show a reduction of proteinuria in the iptacopan arm. Upon completion at 24 months, the slope of eGFR decline will also be evaluated.<xref ref-type="bibr" rid="article-23357.r87">[87]</xref><xref ref-type="bibr" rid="article-23357.r88">[88]</xref></p>
        <p><bold>Other medications:</bold> Additional&#x000a0;medications, such as cyclophosphamide, azathioprine, calcineurin inhibitors, and leflunomide, have been investigated for their potential efficacy in IgAN. These drugs primarily exert their effects on T- and B cells. Although results vary, currently, clear evidence demonstrating a significant benefit from these agents does not exist.<xref ref-type="bibr" rid="article-23357.r73">[73]</xref><xref ref-type="bibr" rid="article-23357.r89">[89]</xref><xref ref-type="bibr" rid="article-23357.r90">[90]</xref><xref ref-type="bibr" rid="article-23357.r91">[91]</xref><xref ref-type="bibr" rid="article-23357.r92">[92]</xref></p>
        <p>
<bold>Combination Therapy</bold>
</p>
        <p>Combination therapy involving corticosteroids along with another agent is typically considered for cases of progressive IgAN. A randomized prospective trial focusing on high-risk IgAN patients showed improved renal survival in those receiving prednisone along with cyclophosphamide or azathioprine compared to those without immunotherapy.<xref ref-type="bibr" rid="article-23357.r93">[93]</xref>&#x000a0;However, results reported in another multicenter trial found no significant difference between patients treated with corticosteroids alone and those receiving combination therapy.<xref ref-type="bibr" rid="article-23357.r94">[94]</xref></p>
        <p>
<bold>Tonsillectomy</bold>
</p>
        <p>The tonsils are a significant store for MALT, and&#x000a0;IgA levels are known to decrease post-tonsillectomy. In addition, a correlation exists between tonsillar dendritic cell concentration and crescent formation in IgAN patients. Multiple retrospective studies have demonstrated the benefits of tonsillectomy in inducing remission or slowing IgAN progression, particularly in Asian populations, notably Japan.<xref ref-type="bibr" rid="article-23357.r95">[95]</xref><xref ref-type="bibr" rid="article-23357.r96">[96]</xref><xref ref-type="bibr" rid="article-23357.r97">[97]</xref><xref ref-type="bibr" rid="article-23357.r98">[98]</xref>&#x000a0;Tonsillectomy in conjunction with pulse steroid therapy has also been more recently studied and found to be effective in progressive IgAN.<xref ref-type="bibr" rid="article-23357.r99">[99]</xref><xref ref-type="bibr" rid="article-23357.r100">[100]</xref><xref ref-type="bibr" rid="article-23357.r101">[101]</xref>&#x000a0;Timing of a tonsillectomy with pulse steroids immediately before and after may provide augmented results.<xref ref-type="bibr" rid="article-23357.r102">[102]</xref></p>
        <p>However, the efficacy of tonsillectomy in IgAN management has not been consistently demonstrated in randomized controlled trials, leading to its exclusion from standard care guidelines in many regions, particularly outside of Asia.<xref ref-type="bibr" rid="article-23357.r50">[50]</xref><xref ref-type="bibr" rid="article-23357.r103">[103]</xref>&#x000a0;Additionally, variations of IgAN observed in Asian populations may respond differently to tonsillectomy compared to non-Asian forms, possibly due to differences in incidence rates and disease aggressiveness.</p>
        <p>
<bold>Renal Transplant</bold>
</p>
        <p>For individuals who progress to ESRD from IgAN, renal transplantation is a&#x000a0;viable option. However,&#x000a0;the risk of IgAN recurrence in the transplanted kidney persists. A significant study reported a recurrence rate of 23% in transplanted kidneys at 15 years, correlating with a 3.7-fold increase in graft rejection.<xref ref-type="bibr" rid="article-23357.r104">[104]</xref>&#x000a0;Despite the recurrence of IgA deposits in the transplanted kidney, progression to recurrent ESRD with the grafted kidney is rare. Utilizing anti-thymocyte globulin and maintaining immunosuppression with corticosteroids can mitigate the recurrence of IgAN.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref>&#x000a0;In addition, treatment with ACE inhibitors or ARBs may help delay the progression of recurrent disease in allografts.<xref ref-type="bibr" rid="article-23357.r105">[105]</xref>&#x000a0;</p>
        <p>
<bold>Future Horizons&#x000a0;</bold>
</p>
        <p>Recent advancements in understanding the pathways involved in IgAN have spurred&#x000a0;the development and evaluation of numerous potential therapeutic agents (see&#x000a0;<bold>Image.</bold> New Drugs Under Evaluation for Treatment of IgA Nephropathy and <bold>Image.</bold>&#x000a0;New Prospective Therapy Targeting the Gut Mucosal Immune System).&#x000a0;These medications, currently in the pipeline, span various categories targeting different steps of the disease processes, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Endothelin receptor agonists: These are believed to modulate the hemodynamic aspect of IgAN. Among these, Sparsentan is a prominent example, albeit also functioning as an ARB. Moreover, several other drugs within this class are undergoing investigation for their efficacy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>B-cell inhibitors: B-cell inhibitors are gaining attention for their potential in tackling IgAN, as B cells are responsible for producing deficient IgA1 molecules. Interventions targeting B cells and their functions are currently under investigation, particularly focusing on key regulators such as B-cell activating factor (BAFF) and APRIL (a proliferation-inducing ligand), which influence B-cell modulation and class switching to IgA production. Trials exploring therapies aimed at these factors are currently being investigated.<xref ref-type="bibr" rid="article-23357.r64">[64]</xref><xref ref-type="bibr" rid="article-23357.r106">[106]</xref><xref ref-type="bibr" rid="article-23357.r107">[107]</xref><xref ref-type="bibr" rid="article-23357.r64">[64]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Complement activation inhibitors: As previously mentioned, the alternative and lectin complement pathways play a significant role in IgAN deposits, prompting interventions that often target the common pathway, typically at C3, C3a, and C5. Case reports have indicated improvements in patients with IgAN with treatments such as eculizumab, which inhibits C5 cleavage and is utilized in conditions like hemolytic uremic syndrome.<xref ref-type="bibr" rid="article-23357.r108">[108]</xref><xref ref-type="bibr" rid="article-23357.r109">[109]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other investigational agents: Several investigational agents are under scrutiny for their potential in IgAN management, including bortezomib (a proteasome inhibitor), fostamatinib (a tyrosine kinase inhibitor), and nuclear factor erythroid&#x02013;derived 2-related factor agonists. Additionally, small-interfering RNAs are among the array of novel therapies being explored.<xref ref-type="bibr" rid="article-23357.r4">[4]</xref><xref ref-type="bibr" rid="article-23357.r9">[9]</xref><xref ref-type="bibr" rid="article-23357.r73">[73]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23357.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The 2 conditions closely mimicking the symptoms of IgAN are discussed in detail below.</p>
        <p>
<bold>IgA Vasculitis</bold>
</p>
        <p>IgA vasculitis, also known as Henoch-Sch&#x000f6;nlein purpura, is associated with dysregulated IgA deposits, although these deposits primarily affect the small blood vessels of affected organs. Unlike IgAN, which predominantly affects individuals aged 15 and older, IgA vasculitis primarily affects those aged 15 and younger. Microscopically, patients with IgA vasculitis exhibit more capillary and glomerular injury, while IgAN histology is characterized by mesangial proliferation. Some treatments for both conditions overlap due to their autoimmune involvement. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22766">IgA Vasculitis (Henoch-Sch&#x000f6;nlein Purpura</ext-link>," for further information.</p>
        <p>
<bold>Poststreptococcal Glomerulonephritis</bold>
</p>
        <p>Poststreptococcal glomerulonephritis can also manifest in the context of a URI. A key difference is that while IgAN typically presents concurrently with or shortly after a URI, poststreptococcal glomerulonephritis usually arises 2 to 3 weeks following a URI. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22287">Poststreptococcal Glomerulonephritis</ext-link>," for further information.&#x000a0;</p>
        <p>The following list comprises other potential differentials for IgAN:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lupus nephritis (associated with multisystemic presentation)</p>
          </list-item>
          <list-item>
            <p>Membranoproliferative glomerulonephritis (distinguishable on renal biopsy)</p>
          </list-item>
          <list-item>
            <p>Thin basement membrane nephropathy (often characterized by microscopic hematuria and a family history of benign microscopic hematuria)</p>
          </list-item>
          <list-item>
            <p>Alport syndrome (associated with ocular and otic symptoms)</p>
          </list-item>
          <list-item>
            <p>Malignancies ranging from the kidneys to the urethra (should be ruled out in all patients aged 40 or older)</p>
          </list-item>
          <list-item>
            <p>Urolithiasis (typically manifests with colicky pain not associated with IgAN; imaging will demonstrate obstruction)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23357.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Up to 50% of&#x000a0;IgAN patients experience a benign course.<xref ref-type="bibr" rid="article-23357.r55">[55]</xref>&#x000a0;Prognosis can be somewhat predictable, particularly based on the Oxford classification outlined in the Pathology section. Any of the MEST criteria (and crescents) serve as poor prognostic indicators. Isolated microscopic hematuria with mild proteinuria suggests a favorable prognosis, indicating a benign and asymptomatic disease course. Additionally, individuals of East Asian origin are significantly associated with an elevated risk of ESRD (see <bold>Table</bold>&#x000a0;below).<xref ref-type="bibr" rid="article-23357.r33">[33]</xref></p>
        <p>Three risk factors highly associated with dialysis or death include:<xref ref-type="bibr" rid="article-23357.r34">[34]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Proteinuria of 1 g/d or more</p>
          </list-item>
          <list-item>
            <p>Sustained hypertension</p>
          </list-item>
          <list-item>
            <p>Oxford classification MEST-C score (to which some algorithms also include a category for crescents).</p>
          </list-item>
        </list>
        <p>Patients with sustained proteinuria of 1 g/d or higher have a 46-fold increased risk of ESRD than those with less than 500 mg/d.<xref ref-type="bibr" rid="article-23357.r73">[73]</xref>&#x000a0;About half&#x000a0;of the patients with IgAN may obtain complete remission with treatment, whereas the remaining half may show some degree of ongoing disease.<xref ref-type="bibr" rid="article-23357.r73">[73]</xref></p>
        <table-wrap id="article-23357.table0" position="float" orientation="portrait">
          <caption>
            <title>Table.&#x000a0;MEST-C Score</title>
          </caption>
          <table style="width: 800px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 242.641px;" rowspan="1" colspan="1">
<bold>Pathological Characteristics</bold>
</td>
                <td style="width: 274.359px;" rowspan="1" colspan="1">
<bold>Explanations</bold>
</td>
                <td style="width: 332px;" rowspan="1" colspan="1">
<bold>Scoring&#x000a0;Criteria</bold>
</td>
              </tr>
              <tr>
                <td style="width: 242.641px;" rowspan="1" colspan="1">
<p>Mesangial hypercellularity (M)&#x000a0;</p>
</td>
                <td style="width: 274.359px;" rowspan="1" colspan="1">&#x02265;4 Mesangial cells in any mesangial area of a glomerulus</td>
                <td style="width: 332px;" rowspan="1" colspan="1">
<p>M0: Mesangial hypercellularity in &#x02264;50% of glomeruli</p>
<p>M1: Mesangial hypercellularity in &#x0003e;50% of glomeruli</p>
</td>
              </tr>
              <tr>
                <td style="width: 242.641px;" rowspan="1" colspan="1">
<p>Endocapillary hypercellularity (E)&#x000a0;</p>
</td>
                <td style="width: 274.359px;" rowspan="1" colspan="1">An increased number of cells in the glomerular capillary lumen</td>
                <td style="width: 332px;" rowspan="1" colspan="1">
<p>E0: Absence</p>
<p>E1: Presence of any glomeruli showing endocapillary hypercellularity</p>
</td>
              </tr>
              <tr>
                <td style="width: 242.641px;" rowspan="1" colspan="1">
<p>Segmental glomerulosclerosis (S)</p>
</td>
                <td style="width: 274.359px;" rowspan="1" colspan="1">Adhesion or sclerosis that does not involve the entire glomerulus</td>
                <td style="width: 332px;" rowspan="1" colspan="1">
<p>S0: Absence</p>
<p>S1: Presence of any segmental glomerulosclerosis (podocyte hypertrophy/tip lesions should be noted if present)</p>
</td>
              </tr>
              <tr>
                <td style="width: 242.641px;" rowspan="1" colspan="1">
<p>Tubular atrophy/interstitial fibrosis (T)&#x000a0;</p>
</td>
                <td style="width: 274.359px;" rowspan="1" colspan="1">Percentage of tubular atrophy/interstitial fibrosis of cortical area</td>
                <td style="width: 332px;" rowspan="1" colspan="1">
<p>T0: 0-25%</p>
<p>T1: 26%-50%</p>
<p>T2: &#x0003e;50%</p>
</td>
              </tr>
              <tr>
                <td style="width: 242.641px;" rowspan="1" colspan="1">
<p>Cellular/fibrocellular crescents (C)&#x000a0;</p>
</td>
                <td style="width: 274.359px;" rowspan="1" colspan="1">Extracapillary cell proliferation &#x0003e;2 cell layers thick and &#x0003c;50% matrix</td>
                <td style="width: 332px;" rowspan="1" colspan="1">
<p>C0: Absence</p>
<p>C1: Presence of cellular/fibrocellular crescents in &#x0003c;25% of glomeruli</p>
<p>C2: Presence of cellular/fibrocellular crescents in &#x02265;25% of glomeruli</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>A minimum of 8 viable glomeruli is necessary to calculate the MEST-C score accurately. Based on Markowitz G, 2017 (<italic toggle="yes">Nat Rev Nephrol.</italic>&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrneph.2017.67">https://doi.org/10.1038/nrneph.2017.67</ext-link>) and&#x000a0;Pattrapornpisut P, et al (IgA Nephropathy: Core Curriculum 2021.&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.ajkd.2021.01.024">https://doi.org/10.1053/j.ajkd.2021.01.024</ext-link>).</p>
      </sec>
      <sec id="article-23357.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Although only a small percentage of patients diagnosed with IgAN progress to ESRD, due to the high prevalence, its high prevalence makes it a frequent cause of ESRD.<xref ref-type="bibr" rid="article-23357.r54">[54]</xref>&#x000a0;As the disease progresses, complications of renal failure, such as hypertension, edema, anemia, heart failure, and pulmonary edema, may arise. Common adverse effects and complications of both steroid and steroid-sparing therapy include increased risk of infections, hypertension, fluid retention, weight gain, diabetes mellitus, osteoporosis, and iatrogenic Cushing syndrome.<xref ref-type="bibr" rid="article-23357.r72">[72]</xref>&#x000a0;In addition, complications of steroid-sparing agents may include immunosuppression, anaphylaxis, renal injury, and hepatotoxicity.</p>
      </sec>
      <sec id="article-23357.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>A low-antigen diet, which includes restrictions on gluten, meat, and dairy products, is often recommended for individuals with IgAN. Several studies suggest that low-protein diets may slow the deterioration of renal function.<xref ref-type="bibr" rid="article-23357.r110">[110]</xref><xref ref-type="bibr" rid="article-23357.r111">[111]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23357.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education and deterrence strategies are&#x000a0;crucial in managing IgAN, especially considering its susceptibility to minor URIs in genetically predisposed individuals.</p>
        <list list-type="bullet">
          <list-item>
            <p>A minor&#x000a0;URI in IgAN can trigger the disease in genetically susceptible patients.<xref ref-type="bibr" rid="article-23357.r8">[8]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with other autoimmune diseases and a strong family history of IgAN are more likely to have the disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Screening for hematuria is crucial in early detection of the disease, enabling the identification of patients in the asymptomatic stage of the disease progression.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients should receive comprehensive education covering the nature of the disease, the potential progression to ESRD necessitating renal transplantation, the adverse effects associated with steroid therapy, and the critical importance of regular follow-up care.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The importance of adhering to ACE inhibitors or ARBs and any other prescribed therapies&#x000a0;should be reinforced.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dietary recommendations include restrictions on salt, protein, and saturated fat intake.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23357.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>A proposed 4-hit model highlights abnormal mucosal IgA regulation as the central mechanism:</p>
        <list list-type="bullet">
          <list-item>
            <p>Abnormal O-glycosylation of the IgA1 hinge region, leading to increased levels of galactose-deficient IgA1.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Production of anti-glycan antibodies and IgA1 autoantibodies.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Formation of IgA1 immune complexes circulating in the bloodstream and depositing in the kidney.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Activation of mesangial cells, as well as the lectin and alternative complement systems, resulting in the release of cytokines, the deposition of extracellular proteins, and systemic inflammation and fibrosis.</p>
          </list-item>
        </list>
        <p>Other significant issues essential for navigating the diagnosis, treatment, and prognosis of&#x000a0;IgAN are mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Distinguishing primary IgAN from secondary IgAN is crucial, as addressing the underlying disease is necessary for managing secondary cases.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The lectin and alternative complement pathways are highly involved in IgAN pathology.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IgAN exhibits a higher prevalence and appears to have a more aggressive course among individuals of East Asian origin.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Asymptomatic microscopic hematuria often indicates a favorable prognosis, while rapidly progressing disease with crescents observed on biopsy suggests a poorer prognosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The Oxford MEST classification system is utilized to stratify the risk of IgAN patients, with some guidelines considering the presence of crescents while others do not.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>When gross hematuria occurs in individuals aged 40 or older, it warrants a comprehensive evaluation to rule out potential underlying kidney or bladder neoplasms.<xref ref-type="bibr" rid="article-23357.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Differentiating IgAN from IgA vasculitis and poststreptococcal glomerulonephritis is essential due to variations in treatment approaches for each condition.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sparsentan and nefecon are the 2 recently FDA-approved treatments for IgAN.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ongoing clinical trials aim to assess therapeutic agents targeting various steps of the IgAN pathways.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23357.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The clinical trajectory of IgAN typically spans a protracted course during which an interprofessional healthcare team collaboratively manages patient care. Initial detection often occurs through abnormal urinalysis findings during routine screening by primary care providers. Expedient referral to a nephrologist (or pediatric nephrologist) for comprehensive evaluation is imperative. Coexisting autoimmune diseases may necessitate input from rheumatologists, while systemic manifestations may require the expertise of endocrinologists, gastroenterologists, or other specialists. Moreover, patients should be provided with a "steroid card" for reference.</p>
        <p>Pharmacists are critical in educating patients about steroid therapy and facilitating compliance while also maintaining open communication with the clinical team as needed. Laboratory staff must ensure accurate sample collection to prevent false positives for proteinuria. A dietician should design a tailored diet comprising low-salt, low-protein, and low-fat components to support the patient's nutritional needs. Nurses are&#x000a0;integral members of the healthcare team, providing comprehensive patient assessment, counseling, and coordination among various specialties involved in the case. In addition, all interprofessional healthcare team members must maintain accurate patient records and promptly communicate any concerns regarding the patient's progress with the rest of the team to ensure optimal care.&#x000a0;</p>
        <p>Fluid intake should be carefully managed, considering the patient's fluid balance and renal function. In cases where progression to ESRD is anticipated, patients should receive early and comprehensive education about renal replacement therapy options. Social workers are crucial in supporting and guiding patients and their families during this challenging phase. Due to the complexity of IgAN, optimal outcomes are best achieved through the collaborative efforts of an interprofessional healthcare team comprising clinicians, pharmacists, nurses, and allied health professionals dedicated to educating and supporting both the patient and their family.</p>
      </sec>
      <sec id="article-23357.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23357&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23357">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/iga-nephropathy-berger-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23357">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23357/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23357">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23357.s18">
        <fig id="article-23357.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Histopathological Characteristics of IgA Nephropathy. Light microscopy shows a glomerulus with mild-to-moderate mesangial hypercellularity and endocapillary hypercellularity (A and B). Periodic acid-Schiff staining; original magnification &#x000d7;400 (A). Periodic acid-silver methenamine staining; original magnification &#x000d7;400 (B). Immunofluorescence image reveals IgA deposits along the glomerular mesangial area; original magnification &#x000d7;400 (C). Electron microscopy image shows deposits along the mesangium and matrix; original magnification &#x000d7;5000 (D). Zhang S, Chen YL, Liu CL, Xie JY, Sun BD, Liu DZ.&#x000a0;Case report: IgA nephropathy in a patient with antitranscription intermediary factor-1&#x003b3; antibody-positive dermatomyositis.&#x000a0;<italic toggle="yes">Front Immunol. </italic>2022;13:757802. doi: 10.3389/fimmu.2022.757802.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Changes__Biopsy" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23357.s19">
        <fig id="article-23357.image.f2" position="float" orientation="portrait">
          <caption>
            <p>New Drugs Under Evaluation for Treatment of IgA Nephropathy. New drugs are being evaluated for the treatment of IgA nephropathy. These drugs target persistent proteinuria despite months of optimized supportive care. However, it is believed that some of these drugs could be beneficial in managing the most active and progressive cases, including those exhibiting a high presence of crescents. Trimarchi H, Haas M, Coppo R. Crescents and IgA nephropathy: a delicate marriage. <italic toggle="yes">J Clin Med.</italic> 2022;11(13):3569. doi: 10.3390/jcm11133569.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="New__Drugs__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23357.s20">
        <fig id="article-23357.image.f3" position="float" orientation="portrait">
          <caption>
            <p>New Prospective Therapy Targeting the Gut Mucosal Immune System. A new prospective therapy targeting the gut mucosal immune system is being developed for IgA nephropathy. Some of these treatments are currently under investigation and available only in research settings. Gesualdo L, Di Leo V, Coppo R. The mucosal immune system and IgA nephropathy. <italic toggle="yes">Semin Immunopathol.</italic> 2021;43(5):657-668. doi: 10.1007/s00281-021-00871-y.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Gut__Mucosal__2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23357.s21">
        <title>References</title>
        <ref id="article-23357.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pattrapornpisut</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avila-Casado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>IgA Nephropathy: Core Curriculum 2021.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-441</page-range>
            <pub-id pub-id-type="pmid">34247883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Working Group of the International IgA Nephropathy Network and the Renal Pathology Society</collab>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Troyanov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Camilla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Amore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berthoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonsib</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bruijn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emancipator</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferrario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Florquin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Geddes</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Groene</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herzenberg</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Joh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Mezzano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Tomino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weening</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.</article-title>
            <source>Kidney Int</source>
            <year>2010</year>
            <month>May</month>
            <volume>77</volume>
            <issue>10</issue>
            <fpage>921</fpage>
            <page-range>921-7</page-range>
            <pub-id pub-id-type="pmid">20200498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>LQ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological characteristics and prognostic factors of asymptomatic IgA nephropathy.</article-title>
            <source>J Investig Med</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>3</issue>
            <fpage>560</fpage>
            <page-range>560-5</page-range>
            <pub-id pub-id-type="pmid">20215916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodrigues</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>IgA Nephropathy.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Apr</month>
            <day>03</day>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>677</fpage>
            <page-range>677-686</page-range>
            <pub-id pub-id-type="pmid">28159829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Musial</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Derrough</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Konieczny</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krajewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turkmen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kusztal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports.</article-title>
            <source>J Clin Med</source>
            <year>2023</year>
            <month>Apr</month>
            <day>06</day>
            <volume>12</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">37048809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XK</given-names>
              </name>
            </person-group>
            <article-title>The Role of Immune Modulation in Pathogenesis of IgA Nephropathy.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2020</year>
            <volume>7</volume>
            <fpage>92</fpage>
            <pub-id pub-id-type="pmid">32266276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maillard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gharavi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fremeaux-Bacchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Current Understanding of the Role of Complement in IgA Nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>1503</fpage>
            <page-range>1503-12</page-range>
            <pub-id pub-id-type="pmid">25694468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rollino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vischini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy and infections.</article-title>
            <source>J Nephrol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-8</page-range>
            <pub-id pub-id-type="pmid">26800970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajasekaran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Rizk</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>IgA Nephropathy: An Interesting Autoimmune Kidney Disease.</article-title>
            <source>Am J Med Sci</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>361</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-194</page-range>
            <pub-id pub-id-type="pmid">33309134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tomino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Glassock</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2016</year>
            <month>Feb</month>
            <day>11</day>
            <volume>2</volume>
            <fpage>16001</fpage>
            <pub-id pub-id-type="pmid">27189177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Kie</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous remission of IgA nephropathy associated with resolution of hepatitis A.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>1163</fpage>
            <page-range>1163-7</page-range>
            <pub-id pub-id-type="pmid">20932622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhandari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhargava</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>IgA Nephropathy with Wilson's Disease: A Case Report and Literature Review.</article-title>
            <source>Indian J Nephrol</source>
            <year>2021</year>
            <season>Sep-Oct</season>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>474</fpage>
            <page-range>474-477</page-range>
            <pub-id pub-id-type="pmid">34880558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gesualdo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Leo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The mucosal immune system and IgA nephropathy.</article-title>
            <source>Semin Immunopathol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>657</fpage>
            <page-range>657-668</page-range>
            <pub-id pub-id-type="pmid">34642783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canetta</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Glomerular diseases: emerging tests and therapies for IgA nephropathy.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>617</fpage>
            <page-range>617-25</page-range>
            <pub-id pub-id-type="pmid">24071652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takada</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sumida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hazue</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yamanouchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suwabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hayami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hoshino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takaichi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ubara</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy featuring massive wire loop-like deposits in two patients with alcoholic cirrhosis.</article-title>
            <source>BMC Nephrol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>13</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>362</fpage>
            <pub-id pub-id-type="pmid">29237409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaneko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arakawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Utsumi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iino</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Two cases of rapidly progressive nephritic syndrome complicated with alcoholic liver cirrhosis].</article-title>
            <source>Nihon Jinzo Gakkai Shi</source>
            <year>2011</year>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-7</page-range>
            <pub-id pub-id-type="pmid">21370579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gouet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fort</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roblot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mar&#x000e9;chaud</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sudre</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Touchard</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Glomerulopathy with mesangial IgA deposits in primary hemochromatosis].</article-title>
            <source>Rev Med Interne</source>
            <year>1987</year>
            <season>May-Jun</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>311</fpage>
            <page-range>311-2</page-range>
            <pub-id pub-id-type="pmid">3616239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singhal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy secondary to liver disease.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>2393</fpage>
            <pub-id pub-id-type="pmid">30178238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Berthelot</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Food antigens and Transglutaminase 2 in IgA nephropathy: Molecular links between gut and kidney.</article-title>
            <source>Mol Immunol</source>
            <year>2020</year>
            <month>May</month>
            <volume>121</volume>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">32135400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Angelis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Montemurno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Piccolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vannini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lauriero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maranzano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Serrazanetti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dalfino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gobbetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gesualdo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN).</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>e99006</fpage>
            <pub-id pub-id-type="pmid">24922509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy with leucocytoclastic vasculitis.</article-title>
            <source>J Int Med Res</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>3009</fpage>
            <page-range>3009-3014</page-range>
            <pub-id pub-id-type="pmid">29888629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsuchida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Higashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Horii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kurokawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Aberrant mucosal immunoreaction to tonsillar microbiota in immunoglobulin A nephropathy.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>75</fpage>
            <page-range>75-86</page-range>
            <pub-id pub-id-type="pmid">33099625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Rom&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Olmos</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Vela</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Val</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Riancho</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Bronchiolitis obliterans and IgA nephropathy. A new cause of pulmonary-renal syndrome.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>156</volume>
            <issue>2 Pt 1</issue>
            <fpage>665</fpage>
            <page-range>665-8</page-range>
            <pub-id pub-id-type="pmid">9279256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jelicic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mladinov</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rapidly progressive IgA nephritis and sarcoidosis.</article-title>
            <source>Iran J Kidney Dis</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>315</fpage>
            <page-range>315-317</page-range>
            <pub-id pub-id-type="pmid">36178867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Said</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Fidler</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Myeloproliferative neoplasms cause glomerulopathy.</article-title>
            <source>Kidney Int</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>80</volume>
            <issue>7</issue>
            <fpage>753</fpage>
            <page-range>753-9</page-range>
            <pub-id pub-id-type="pmid">21654720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review.</article-title>
            <source>J Int Med Res</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>300060521996868</fpage>
            <pub-id pub-id-type="pmid">33926295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mimura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tojo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kinugasa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uozaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Renal cell carcinoma in association with IgA nephropathy in the elderly.</article-title>
            <source>Am J Med Sci</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>338</volume>
            <issue>5</issue>
            <fpage>431</fpage>
            <page-range>431-2</page-range>
            <pub-id pub-id-type="pmid">19773639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Freedberg</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Segall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mathur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neugut</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review.</article-title>
            <source>Kidney360</source>
            <year>2023</year>
            <month>Aug</month>
            <day>01</day>
            <volume>4</volume>
            <issue>8</issue>
            <fpage>1112</fpage>
            <page-range>1112-1122</page-range>
            <pub-id pub-id-type="pmid">37227924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGrogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franssen</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>The incidence of primary glomerulonephritis worldwide: a systematic review of the literature.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>414</fpage>
            <page-range>414-30</page-range>
            <pub-id pub-id-type="pmid">21068142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Utsunomiya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Koda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kado</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kanzaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kasagi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hayashibara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okasora</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Incidence of pediatric IgA nephropathy.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-5</page-range>
            <pub-id pub-id-type="pmid">12720079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sanna-Cherchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rohanizadegan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eitner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Izzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gigante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gesualdo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Savoldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amoroso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cusi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zamboli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mucha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Perola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kristiansson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Viktorin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Magnusson</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Thorleifsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thorsteinsdottir</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stefansson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thibaudin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jager</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maixnerova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karnib</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Panzer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Berthoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stengel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis.</article-title>
            <source>PLoS Genet</source>
            <year>2012</year>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>e1002765</fpage>
            <pub-id pub-id-type="pmid">22737082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Nistor</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of IgA Nephropathy: A Global Perspective.</article-title>
            <source>Semin Nephrol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>435</fpage>
            <page-range>435-442</page-range>
            <pub-id pub-id-type="pmid">30177015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbour</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hladunewich</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease.</article-title>
            <source>Kidney Int</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>1017</fpage>
            <page-range>1017-24</page-range>
            <pub-id pub-id-type="pmid">23739233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soares</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy: an update.</article-title>
            <source>Curr Opin Nephrol Hypertens</source>
            <year>2017</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-171</page-range>
            <pub-id pub-id-type="pmid">28221174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magistroni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.</article-title>
            <source>Kidney Int</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>88</volume>
            <issue>5</issue>
            <fpage>974</fpage>
            <page-range>974-89</page-range>
            <pub-id pub-id-type="pmid">26376134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moldoveanu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Eison</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Sch&#x000f6;nlein purpura nephritis.</article-title>
            <source>Kidney Int</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-87</page-range>
            <pub-id pub-id-type="pmid">21326171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Moldoveanu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Woodford</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Mestecky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2008</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>1008</fpage>
            <page-range>1008-14</page-range>
            <pub-id pub-id-type="pmid">18272841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nagasawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shoji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwatani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hamano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uehata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsubakihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rakugi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Isaka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Cigarette smoking and progression of IgA nephropathy.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-24</page-range>
            <pub-id pub-id-type="pmid">20471735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kataoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ohara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Maximal glomerular diameter as a 10-year prognostic indicator for IgA nephropathy.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>3937</fpage>
            <page-range>3937-43</page-range>
            <pub-id pub-id-type="pmid">21427079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knoppova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reily</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maillard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rizk</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Moldoveanu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mestecky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Renfrow</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.</article-title>
            <source>Front Immunol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>117</fpage>
            <pub-id pub-id-type="pmid">27148252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sanna-Cherchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verbitsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fasel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Izzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Dallera</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Barlassina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bertinetto</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Amoroso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Savoldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rocchietti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peruzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salvadori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ravani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Magistroni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghiggeri</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Caridi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bodria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lugani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Allegri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Delsante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maiorana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Magnano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frasca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boscutti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ponticelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mignani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marcantoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Landro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Polci</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feriozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chicca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galliani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gigante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gesualdo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zamboli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Battaglia</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Garozzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maixnerov&#x000e1;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Eitner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rauen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mucha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>P&#x00105;czek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zaniew</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizerska-Wasiak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roszkowska-Blaim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pawlaczyk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thibaudin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berthoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Canaud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panzer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Caliskan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stengel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cusi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.</article-title>
            <source>Nat Genet</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>11</issue>
            <fpage>1187</fpage>
            <page-range>1187-96</page-range>
            <pub-id pub-id-type="pmid">25305756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rastaldi</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Calvaresi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oortwijn</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Schlagwein</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>van Gijlswijk-Janssen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Kooten</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Daha</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1724</fpage>
            <page-range>1724-34</page-range>
            <pub-id pub-id-type="pmid">16687629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bouwman</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>van Gijlswijk-Janssen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Faber-Krol</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Daha</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Human IgA activates the complement system via the mannan-binding lectin pathway.</article-title>
            <source>J Immunol</source>
            <year>2001</year>
            <month>Sep</month>
            <day>01</day>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>2861</fpage>
            <page-range>2861-8</page-range>
            <pub-id pub-id-type="pmid">11509633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sanna-Cherchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Men</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yasuno</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gunel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Umlauf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tikhonova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beerman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Savoldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Magistroni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghiggeri</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bodria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lugani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ravani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ponticelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Allegri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boscutti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frasca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Amore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peruzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Izzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Prati</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salvadori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mignani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gesualdo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bertinetto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mesiano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amoroso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide association study identifies susceptibility loci for IgA nephropathy.</article-title>
            <source>Nat Genet</source>
            <year>2011</year>
            <month>Mar</month>
            <day>13</day>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-7</page-range>
            <pub-id pub-id-type="pmid">21399633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moldoveanu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Renfrow</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mestecky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>The pathophysiology of IgA nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>1795</fpage>
            <page-range>1795-803</page-range>
            <pub-id pub-id-type="pmid">21949093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassler</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy: A brief review.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2020</year>
            <month>May</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>143</fpage>
            <page-range>143-147</page-range>
            <pub-id pub-id-type="pmid">32241578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kusaba</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ohsawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inoshita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanifuji</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamoto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Horikoshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tomino</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Significance of broad distribution of electron-dense deposits in patients with IgA nephropathy.</article-title>
            <source>Med Mol Morphol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-34</page-range>
            <pub-id pub-id-type="pmid">22431181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trimarchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Crescents and IgA Nephropathy: A Delicate Marriage.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Jun</month>
            <day>21</day>
            <volume>11</volume>
            <issue>13</issue>
            <pub-id pub-id-type="pmid">35806856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kataoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ohara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shibui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Honda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>706</fpage>
            <page-range>706-12</page-range>
            <pub-id pub-id-type="pmid">22350469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Appel</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Waldman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The IgA nephropathy treatment dilemma.</article-title>
            <source>Kidney Int</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>69</volume>
            <issue>11</issue>
            <fpage>1939</fpage>
            <page-range>1939-44</page-range>
            <pub-id pub-id-type="pmid">16641925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical course and prognostic factors of clinical early IgA nephropathy.</article-title>
            <source>Neth J Med</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>242</fpage>
            <page-range>242-7</page-range>
            <pub-id pub-id-type="pmid">18689907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Amico</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome.</article-title>
            <source>Semin Nephrol</source>
            <year>2004</year>
            <month>May</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-96</page-range>
            <pub-id pub-id-type="pmid">15156525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Vallance-Owen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>An overlapping syndrome of IgA nephropathy and lipoid nephrosis.</article-title>
            <source>Am J Clin Pathol</source>
            <year>1986</year>
            <month>Dec</month>
            <volume>86</volume>
            <issue>6</issue>
            <fpage>716</fpage>
            <page-range>716-23</page-range>
            <pub-id pub-id-type="pmid">3538845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herlitz</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy with minimal change disease.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>06</day>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>1033</fpage>
            <page-range>1033-9</page-range>
            <pub-id pub-id-type="pmid">24721885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benediktsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Manns</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hemmelgarn</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Histopathologic features aid in predicting risk for progression of IgA nephropathy.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>425</fpage>
            <page-range>425-30</page-range>
            <pub-id pub-id-type="pmid">20089495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Working Group of the International IgA Nephropathy Network and the Renal Pathology Society</collab>
              <name>
                <surname>Roberts</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Troyanov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Amore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berthoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonsib</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bruijn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emancipator</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Emma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferrario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Florquin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geddes</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Groene</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herzenberg</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Joh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Mackinnon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mezzano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Tomino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weening</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yoshikawa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.</article-title>
            <source>Kidney Int</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>76</volume>
            <issue>5</issue>
            <fpage>546</fpage>
            <page-range>546-56</page-range>
            <pub-id pub-id-type="pmid">19571790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herzenberg</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Troyanov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bavbek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Massat</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hunley</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Hladunewich</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Validation of the Oxford classification of IgA nephropathy.</article-title>
            <source>Kidney Int</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>310</fpage>
            <page-range>310-7</page-range>
            <pub-id pub-id-type="pmid">21544062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>The Oxford classification as a predictor of prognosis in patients with IgA nephropathy.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>252</fpage>
            <page-range>252-8</page-range>
            <pub-id pub-id-type="pmid">21606384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trimarchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Yuzawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
              <collab>IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society</collab>
              <collab>Conference Participants</collab>
            </person-group>
            <article-title>Oxford Classification of IgA nephropathy 2016: an&#x000a0;update from the IgA Nephropathy Classification Working Group.</article-title>
            <source>Kidney Int</source>
            <year>2017</year>
            <month>May</month>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>1014</fpage>
            <page-range>1014-1021</page-range>
            <pub-id pub-id-type="pmid">28341274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rovin</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bridoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Burdge</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Glassock</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liew</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Mej&#x000ed;a-Vilet</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rave</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SCW</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vivarelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wetzels</surname>
                <given-names>JFM</given-names>
              </name>
              <name>
                <surname>Lytvyn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tunnicliffe</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Earley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>753</fpage>
            <page-range>753-779</page-range>
            <pub-id pub-id-type="pmid">34556300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berthoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thibaudin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yanagawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maillard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mariat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tomino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>1579</fpage>
            <page-range>1579-87</page-range>
            <pub-id pub-id-type="pmid">22904352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moldoveanu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Tomana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Mestecky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>WQ</given-names>
              </name>
              <name>
                <surname>Anreddy</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.</article-title>
            <source>Kidney Int</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>11</issue>
            <fpage>1148</fpage>
            <page-range>1148-54</page-range>
            <pub-id pub-id-type="pmid">17342176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of IgA nephropathy.</article-title>
            <source>J Nephrol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-5</page-range>
            <pub-id pub-id-type="pmid">26577268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nozaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kumai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy.</article-title>
            <source>Cell Immunol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>341</volume>
            <fpage>103925</fpage>
            <pub-id pub-id-type="pmid">31088610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rauen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eitner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fitzner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sommerer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zeier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Panzer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Benck</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Kuhlmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Witzke</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vielhauer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hilgers</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <collab>STOP-IgAN Investigators</collab>
            </person-group>
            <article-title>Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Dec</month>
            <day>03</day>
            <volume>373</volume>
            <issue>23</issue>
            <fpage>2225</fpage>
            <page-range>2225-36</page-range>
            <pub-id pub-id-type="pmid">26630142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rauen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eitner</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Mar</month>
            <day>10</day>
            <volume>374</volume>
            <issue>10</issue>
            <fpage>992</fpage>
            <page-range>992-3</page-range>
            <pub-id pub-id-type="pmid">26962736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rauen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wied</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fitzner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eitner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sommerer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zeier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Panzer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Benck</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Kuhlmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Witzke</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vielhauer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>JFE</given-names>
              </name>
              <name>
                <surname>Hilgers</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <collab>STOP-IgAN Investigators</collab>
            </person-group>
            <article-title>After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.</article-title>
            <source>Kidney Int</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>1044</fpage>
            <page-range>1044-1052</page-range>
            <pub-id pub-id-type="pmid">32450154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selvaskandan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Novel Treatment Paradigms: Primary IgA Nephropathy.</article-title>
            <source>Kidney Int Rep</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-213</page-range>
            <pub-id pub-id-type="pmid">38344739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kittiskulnam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kanjanabuch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tangmanjitjaroen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chancharoenthana</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Praditpornsilpa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eiam-Ong</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial.</article-title>
            <source>J Ren Nutr</source>
            <year>2014</year>
            <month>May</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>200</fpage>
            <page-range>200-7</page-range>
            <pub-id pub-id-type="pmid">24759301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Cigarette smoking may accelerate the progression of IgA nephropathy.</article-title>
            <source>BMC Nephrol</source>
            <year>2021</year>
            <month>Jun</month>
            <day>29</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>239</fpage>
            <pub-id pub-id-type="pmid">34187402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Scolari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Frasca</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ghiggeri</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amoroso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viola</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Battini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caridi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Canova</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Farhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nelson-Williams</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Woodford</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lifton</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23.</article-title>
            <source>Nat Genet</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>354</fpage>
            <page-range>354-7</page-range>
            <pub-id pub-id-type="pmid">11062479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <collab>TESTING Study Group</collab>
            </person-group>
            <article-title>Corticosteroid therapy in IgA nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>1108</fpage>
            <page-range>1108-16</page-range>
            <pub-id pub-id-type="pmid">22539830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Natale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ruospo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saglimbene</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Vecchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Molony</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Schena</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Strippoli</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppressive agents for treating IgA nephropathy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Mar</month>
            <day>12</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD003965</fpage>
            <pub-id pub-id-type="pmid">32162319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hladunewich</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hooi</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Monaghan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Glassock</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Billot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Cass</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <collab>TESTING Study Group</collab>
            </person-group>
            <article-title>The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.</article-title>
            <source>Am J Nephrol</source>
            <year>2021</year>
            <volume>52</volume>
            <issue>10-11</issue>
            <fpage>827</fpage>
            <page-range>827-836</page-range>
            <pub-id pub-id-type="pmid">34731857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Hladunewich</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hooi</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Monaghan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Glassock</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Billot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stepien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Cass</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Remuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <collab>TESTING Study Group</collab>
            </person-group>
            <article-title>Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>May</month>
            <day>17</day>
            <volume>327</volume>
            <issue>19</issue>
            <fpage>1888</fpage>
            <page-range>1888-1898</page-range>
            <pub-id pub-id-type="pmid">35579642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Sparsentan: First Approval.</article-title>
            <source>Drugs</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>83</volume>
            <issue>6</issue>
            <fpage>563</fpage>
            <page-range>563-568</page-range>
            <pub-id pub-id-type="pmid">37022667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heerspink</surname>
                <given-names>HJL</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bieler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diva</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Inrig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Komers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mercer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Noronha</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Rheault</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Rote</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rovin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trachtman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trimarchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <collab>PROTECT Investigators</collab>
            </person-group>
            <article-title>Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.</article-title>
            <source>Lancet</source>
            <year>2023</year>
            <month>May</month>
            <day>13</day>
            <volume>401</volume>
            <issue>10388</issue>
            <fpage>1584</fpage>
            <page-range>1584-1594</page-range>
            <pub-id pub-id-type="pmid">37015244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rovin</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heerspink</surname>
                <given-names>HJL</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bieler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Diva</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gesualdo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Inrig</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kohan</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Komers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kooienga</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lafayette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ma&#x00142;ecki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mercer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Noronha</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Peh</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Praga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Preciado</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rheault</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Rote</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SCW</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Trachtman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trimarchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tumlin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <collab>DUPRO steering committee and PROTECT Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2023</year>
            <month>Dec</month>
            <day>02</day>
            <volume>402</volume>
            <issue>10417</issue>
            <fpage>2077</fpage>
            <page-range>2077-2090</page-range>
            <pub-id pub-id-type="pmid">37931634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smerud</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>B&#x000e1;r&#x000e1;ny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lindstr&#x000f6;m</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fernstr&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sandell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P&#x000e5;hlsson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fellstr&#x000f6;m</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>3237</fpage>
            <page-range>3237-42</page-range>
            <pub-id pub-id-type="pmid">21378156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lafayette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Trimarchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eren</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Paliege</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rovin</surname>
                <given-names>BH</given-names>
              </name>
              <collab>NefIgArd Trial Investigators</collab>
            </person-group>
            <article-title>Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.</article-title>
            <source>Kidney Int</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>391</fpage>
            <page-range>391-402</page-range>
            <pub-id pub-id-type="pmid">36270561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fellstr&#x000f6;m</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Fijter</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hetzel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Mercer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Praga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>L</given-names>
              </name>
              <collab>NEFIGAN Trial Investigators</collab>
            </person-group>
            <article-title>Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>May</month>
            <day>27</day>
            <volume>389</volume>
            <issue>10084</issue>
            <fpage>2117</fpage>
            <page-range>2117-2127</page-range>
            <pub-id pub-id-type="pmid">28363480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>SGLT-2 inhibition in IgA nephropathy: the new standard of care?</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-26</page-range>
            <pub-id pub-id-type="pmid">33878337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Holzman</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Trachtman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Waldman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-41</page-range>
            <pub-id pub-id-type="pmid">23871408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.</article-title>
            <source>BMC Nephrol</source>
            <year>2014</year>
            <month>Dec</month>
            <day>05</day>
            <volume>15</volume>
            <fpage>193</fpage>
            <pub-id pub-id-type="pmid">25475967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Che</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mou</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>1137</fpage>
            <page-range>1137-47</page-range>
            <pub-id pub-id-type="pmid">25892092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lafayette</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Canetta</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rovin</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Appel</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nath</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tumlin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Enders</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knoppova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>1306</fpage>
            <page-range>1306-1313</page-range>
            <pub-id pub-id-type="pmid">27821627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizk</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Rovin</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kashihara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trimarchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kollins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Papachristofi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Charney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.</article-title>
            <source>Kidney Int Rep</source>
            <year>2023</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>968</fpage>
            <page-range>968-979</page-range>
            <pub-id pub-id-type="pmid">37180505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rizk</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kashihara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rovin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Trimarchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sprangers</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kollins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Papachristofi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Milojevic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Junge</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nidamarthy</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Charney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.</article-title>
            <source>Kidney Int</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>105</volume>
            <issue>1</issue>
            <fpage>189</fpage>
            <page-range>189-199</page-range>
            <pub-id pub-id-type="pmid">37914086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment of IgA nephropathy: Recent advances and prospects.</article-title>
            <source>Nephrol Ther</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14 Suppl 1</volume>
            <fpage>S13</fpage>
            <page-range>S13-S21</page-range>
            <pub-id pub-id-type="pmid">29606258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>The Treatment of IgA Nephropathy.</article-title>
            <source>Kidney Dis (Basel)</source>
            <year>2015</year>
            <month>May</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-26</page-range>
            <pub-id pub-id-type="pmid">27536661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>KN</given-names>
              </name>
            </person-group>
            <article-title>Long-term study of mycophenolate mofetil treatment in IgA nephropathy.</article-title>
            <source>Kidney Int</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>543</fpage>
            <page-range>543-9</page-range>
            <pub-id pub-id-type="pmid">20032964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feehally</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>An update on the treatment of IgA nephropathy.</article-title>
            <source>Curr Opin Nephrol Hypertens</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>319</fpage>
            <page-range>319-326</page-range>
            <pub-id pub-id-type="pmid">28399021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballardie</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>ISD</given-names>
              </name>
            </person-group>
            <article-title>Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>142</fpage>
            <page-range>142-148</page-range>
            <pub-id pub-id-type="pmid">11752031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andrulli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scaini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roccatello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fogazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pecchini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rustichelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Finocchiaro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.</article-title>
            <source>J Nephrol</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-93</page-range>
            <pub-id pub-id-type="pmid">22460183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maeda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kishida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitabayashi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Okumura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Imanishi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>2806</fpage>
            <page-range>2806-13</page-range>
            <pub-id pub-id-type="pmid">22492824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karasawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>295</fpage>
            <page-range>295-306</page-range>
            <pub-id pub-id-type="pmid">31845064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Otani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Minami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Negi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yukawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shigematsu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Tonsillectomy with steroid pulse therapy has more effect on the relapse rate than steroid pulse monotherapy in IgA nephropathy patients.</article-title>
            <source>Clin Nephrol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-52</page-range>
            <pub-id pub-id-type="pmid">23557791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gejyo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy.</article-title>
            <source>Kidney Int</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>1135</fpage>
            <page-range>1135-44</page-range>
            <pub-id pub-id-type="pmid">15086452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe-Kusunoki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaneshima</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakagaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maoka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukasawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishimoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atsumi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Comparison of administration of single- and triple-course steroid pulse therapy combined with tonsillectomy for immunoglobulin A nephropathy.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2021</year>
            <month>Dec</month>
            <day>17</day>
            <volume>100</volume>
            <issue>50</issue>
            <fpage>e27778</fpage>
            <pub-id pub-id-type="pmid">34918629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wakai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nitta</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparison between consecutive and intermittent steroid pulse therapy combined with tonsillectomy for clinical remission of IgA nephropathy.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-8</page-range>
            <pub-id pub-id-type="pmid">23744063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komatsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tonsillectomy combined with steroid pulse therapy induces clinical remission of IgA nephropathy.</article-title>
            <source>Adv Otorhinolaryngol</source>
            <year>2011</year>
            <volume>72</volume>
            <fpage>57</fpage>
            <page-range>57-9</page-range>
            <pub-id pub-id-type="pmid">21865690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adachi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hotta</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hozawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taguma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Katori</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Steroid pulse therapy transiently destroys the discriminative histological structure of tonsils in IgA nephropathy: Tonsillectomy should be performed before or just after steroid pulse therapy.</article-title>
            <source>Auris Nasus Larynx</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>1206</fpage>
            <page-range>1206-1213</page-range>
            <pub-id pub-id-type="pmid">29789195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feriozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Polci</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The role of tonsillectomy in IgA nephropathy.</article-title>
            <source>J Nephrol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-9</page-range>
            <pub-id pub-id-type="pmid">26582216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uffing</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Sa&#x000e9;z</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jouve</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bugnazet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malvezzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Muhsin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lafargue</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Reindl-Schwaighofer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morlock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oberbauer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Buxeda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burballa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>von Moos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>La Manna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Comai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Farouk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nissaisorakarn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mastroianni-Kirsztajn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mansur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tedesco-Silva</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ventura</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Agena</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>David-Neto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Akalin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alani</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mazzali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manfro</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>XS</given-names>
              </name>
              <name>
                <surname>Schold</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Cravedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Riella</surname>
                <given-names>LV</given-names>
              </name>
            </person-group>
            <article-title>Recurrence of IgA Nephropathy after Kidney Transplantation in Adults.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>1247</fpage>
            <page-range>1247-1255</page-range>
            <pub-id pub-id-type="pmid">34362788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Courtney</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>McNamee</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>3550</fpage>
            <page-range>3550-4</page-range>
            <pub-id pub-id-type="pmid">16968729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myette</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Szretter</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Adari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deotale</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Engler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shriver</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wollacott</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>BJG</given-names>
              </name>
            </person-group>
            <article-title>A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.</article-title>
            <source>Kidney Int</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>96</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <page-range>104-116</page-range>
            <pub-id pub-id-type="pmid">31027890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhai</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>95</volume>
            <issue>11</issue>
            <fpage>e3099</fpage>
            <pub-id pub-id-type="pmid">26986150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaartinen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Safa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kotha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ratti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Meri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Complement dysregulation in glomerulonephritis.</article-title>
            <source>Semin Immunol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>45</volume>
            <fpage>101331</fpage>
            <pub-id pub-id-type="pmid">31711769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizk</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Maillard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Knoppova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wyatt</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.</article-title>
            <source>Front Immunol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>504</fpage>
            <pub-id pub-id-type="pmid">30941137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luvizotto</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Menezes-Silva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Woronik</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>C&#x000e2;mara</surname>
                <given-names>NOS</given-names>
              </name>
            </person-group>
            <article-title>Gut-kidney axis in IgA nephropathy: Role on mesangial cell metabolism and inflammation.</article-title>
            <source>Front Cell Dev Biol</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>993716</fpage>
            <pub-id pub-id-type="pmid">36467425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23357.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Puccini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Longombardo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paleologo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Migliorini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moriconi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pasero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cioni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Low-antigen-content diet in the treatment of patients with IgA nephropathy.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>1993</year>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>1193</fpage>
            <page-range>1193-8</page-range>
            <pub-id pub-id-type="pmid">8302454</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
